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Vaccination of cattle with the recombinant E7 protein of bovine papillomavirus type 4 (BPV-4) prior to BPV-4 infection 
has been shown to retard development of papillomas and accelerate their regression. To understand the mechanism of 
regression we have measured proliferation of peripheral blood mononuclear cells (PBM) to E7 in vitro during the course 
of BPV-4 infection in both vaccinated and nonvaccinated cattle. In vaccinated cattle, T cells specific for E7 could be detected 
at high levels shortly after challenge, whereas in nonvaccinated cattle low responses of E7-specific T cells could be detected 
in only a few animals at the late stages of papilloma development. Using short overlapping synthetic peptides corresponding 
to the E7 protein, three T cell epitopes have been identified. T1 (aa 31-59) was immunodominant and T2 (aa 70-88) and 
T3 (aa21-40) were minor epitopes. © 1995 Academic Press, Inc. 
INTRODUCTION 
Papillomaviruses can infect and cause proliferative le- 
sions in both cutaneous and mucous epithelia. The virus- 
induced tumours are normally benign and regress spon- 
taneously, with a few exceptions. Human papillomavirus 
type 16 (HPV-16) has been frequently implicated with 
squamous cell carcinoma of the cervix (zur Hausen, 
1991) and BPV-4 with alimentary canal cancer in cattle 
(Campo, 1992). Given its association with cancer, it fol- 
lows that a vaccine against the virus either preventing 
infection or controlling preexisting lesions at an early 
stage would prevent development of cancer. The immune 
response to papillomaviruses is still unclear but an un- 
derstanding of the immunology will be helpful in the de- 
velopment of a vaccine. Circumstantial evidence has im- 
plicated cell mediated immunity in the control of papillo- 
mavirus infection, Individuals with primary or secondary 
cellular immunodeficiency have persistent infections (Be- 
nton et al., 1992). Other evidence for the importance of 
a cellular immune response to papitlomavirus is the ob- 
servation of infiltration of lymphocytes into regressing 
BPV-2-induced papillomas of cattle (Jarrett et al., 1991), 
in cottontail rabbit papillomavirus lesions (Okabayashi et 
al., 1993), and in flat warts in humans (Tagami et aL, 
1974; Berman and Winkelman, 1977). The possibility of 
direct experimentation i  animal systems allows vaccina- 
tion studies and the analysis of the immune response of 
a host to its natural pathogen over time. BPV-4 infection 
of the alimentary canal in cattle leads to the development 
of papillomas which can progress to cancer in the pres- 
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ence of cofactors such as feeding on bracken fern, which 
contains immunosuppressants (Evans et al., 1982a) and 
mutagens (Evans et al., 1982b). We have previously re- 
ported that vaccinating cattle with recombinant E7 of 
BPV-4 retards tumour growth and accelerates regression 
of BPV-4-induced papillomas (Campo et al., 1993). E7 
specific antibodies have been detected in the sera of 
vaccinated animals and three immunodominant B cell 
epitopes have been identified on the protein (Chandra- 
chud et aL, 1994). This paper extends the study of the 
immune response to E7 in control (nonvaccinated) and 
vaccinated cattle by analysing the response of T ceils to 
E7 protein and mapping T cell epitopes. 
MATERIALS  AND METHODS 
iS -Ga lactos idase  E7 fusion prote ins 
The early E7 open reading frame (ORF) was cloned in 
pUR or pGEX plasmids to produce /~-galactosidase 
(~Gal) or glutathione-S-transferase (GST) fusion prod- 
ucts, respectively, as previously described by Campo et 
aL (1993). Briefly, the E70RF, representing full-length E7, 
was isolated as a Bsrl fragment [nucleotides (nt) 652- 
1249] and cloned into pUR278 by the addition of BamHI 
linkers or into pGEX3x by blunt end cloning into the Sma 
site. The recombinant was transfected into Escher/chia 
cof i JMl09,  grown and induced by IPTG./~Gal, GST, and 
the corresponding E7 fusion products were partially puri- 
fied by lysis of the bacteria and then further purified by 
SDS continuous-flow gel eiectrophoresis. The proteins 
were precipitated by acetone and then resuspended in 
RPMI 1640 (Life Technologies) for use in proliferation 
assays. 
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BPV-4  E7  PEPT IDES 
MKGQNvTLQDIAIELEDTI•PINLH•EEEIETEEvDTPNPFAITATCYACEQvLRLAvvTSTEGIHQLQQLLFDNLFLLCAACS•QVFCNRRPERNGP 
158 MKGQNVTLQDIAIELEDTIS (1-20) 
159 IAIELEDTISPINLHCEEEI (11-30) 
160 PINLHCEEEIETEEVDTPNP (21-40) 
161 ETEEVDTPNPFAITATCYA (31-49) 
167 PNPFAITATCYACEQVLR (37-55) 
162 FAITATCYACEQVLRLAW (41-59) 
163 CEQVLRLAVVTSTEGIHQLQ (50-69) 
164 TSTEGIHQLQQLLFDNLFL (60-78) 
165 QLLFDNLFLLCAACSKQVF (70-88) 
166 LCAACSKQVFCNRRPERNGP (79-98) 
FIG. 1. Overlapping BPV-4 E7 synthetic peptides, Amino acid limits ofthe peptides are shown on the rightand the number ofthe corresponding 
peptide on the le~forease  ofreference. 
Vaccination 
Calves approximately 12 weeks of age were divided 
into two groups, group 1 with 11 animals (Nos. 1-11) 
and group 2 with 8 animals (Nos. 12-19; N.B. animals 
12, 15, and 16 are the same as 25, 26, and 27 in Chandra- 
chud eta/., 1994). Each animal in group 1 was given two 
vaccinations of 1 mg /gGaI-E7 in Freund's incomplete 
adjuvant 4 weeks apart and then 2 weeks after the sec- 
ond vaccination, animals in both groups were challenged 
in the palate with 1011 particles of BPV-4. 
Proliferation assays 
Fifty milliliters of blood was removed from each animal 
at 3- or 4-week intervals throughout the trial. Blood was 
separated on lymphoprep (Nycomed UK) and peripheral 
blood mononuclear cells (PBM) removed from the inter- 
face. PBM were stored in liquid nitrogen. Proliferation 
assays were performed, with either fresh or frozen cells, 
in 96-well flat-bottomed plates. PBM at 3 x 10 ~ cells/ 
well in RPMI 1640 supplemented with 10% heat-inacti- 
vated fetal calf serum and 50 #M mercaptoethanol were 
cultured in medium alone or in the presence of 5 fig 
~Gal or/3GaI-E7. Cells were cultured for a total of 72 
hr with 1 #Ci/well methyl-[3H]thymidine for the last 6 
hr. Harvesting was by an automatic cell harvester and 
incorporation was measured by a beta plate counter. 
Each assay was performed in triplicate. The results are 
presented as a stimulation index (SI); the incorporation 
of [3H]thymidine in cells exposed to/3Gal was deducted 
from that of cells exposed to/3GaI-E7 to give the incor- 
poration specific for E7.. SI = cpm(flGaI-E7) - cpm 
(/3Gal)/cpm (no antigen). A SI i> 2 was considered posi- 
tive. 
Peptides 
Peptides 19 or 20 amino acids long overlapping by 10 
amino acids corresponding to the entire E7 protein were 
synthesised and were designated 158-167 (Fig. 1) (Bio- 
mac, Ltd., Department of Biochemistry, University of Glas- 
gow). Individual peptides were used in proliferation 
assays to determine the T cell epitopes of the E7 protein. 
Proliferation to peptides 
PBM that responded to E7 in proliferation assays were 
cultured at 1.5 X 10 6 cells/ml in 24-well tissue culture 
plates for 7 days in the presence of 25 #g/ml of either 
/3GaI-E7 or GST-E7 followed by 7 days with 20 units/ 
ml recombinant human interleukin 2. Proliferation assays 
were carried out in 96-well flat-bottomed plates. Each 
well contained 1 x 105 cells after culture, 4 #g of peptide, 
and 2 X 10 ~ autologous antigen presenting cells after 
irradiation at 30 Gy. Proliferation assays were for a total 
of 72 hr with methyl-[3H]thymidine present for the last 6 
hr. Cells were harvested as described above. Results 
are presented as a stimulation index: SI = cpm (peptide)/ 
cpm (no peptide). A SI i> 2 was considered positive. 
RESULTS 
E7 promotes early regression of papillomas 
Immunisation of cattle with /3Gal E7 retarded the full 
development of papillomas and promoted their early re- 
gression (Campo et aL, 1993). Vaccinated cattle did not 
develop papillomas beyond stage 2 (papillomas < 2 mm) 
compared to nonvaccinated cattle which developed 
stage 3 papillomas (> 2 mm). Stage 2 papillomas in the 
vaccinated group started to decline in numbers 13 weeks 
after virus challenge and the animals were papilloma 
free by 25 weeks postchallenge. In the control group 
stage 2 papillomas progressed to stage 3 papillomas and 
regression did not start until 25 weeks after challenge. 
T cell response to E7 
In vitro proliferation of PBM in response to E7 from 
both vaccinated and control cattle was determined at 3- 
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FIG. 2. Proliferative response of bovine PBM to E7 protein from E7-vaccinated animals (A, B, and C) and control animals (D) before and after 
challenge with BPV-4. PBM were stimulated in vitro with 5 #g ~'Gal, 5 #g /~'Gal E7, or no antigen; each condition was performed in triplicate. 
Results are presented as stimulation indices and are specific responses to E7. SI = cpm/~GaI-E7 - cpm ~Gal/cpm (no antigen). The experimental 
number of each animal is next to the symbol box. The line represents SI = 2 and anything above this is considered positive. Error bars are not 
presented for responses at baseline levels. 
to 4-week intervals throughout the vaccination trial be- 
fore and after chal lenge (Fig. 2), to determine the T cell 
response to E7 at each stage of papi l loma development 
and regression. PBM that were assayed more than once 
gave comparable and reproducible responses to E7. T 
cells activated by antigen in vivo can respond to the 
antigen in vitro and proliferate. PBM from all animals did 
not respond to E7 before vaccination ( -6  weeks). PBM 
from animals in the vaccinated group proliferated to E7 
between 7 and 17 weeks after chal lenge (Figs. 2A, 2B, 
and 2C). In this group the number of stage 2 papi l lomas 
had declined by 13 weeks after chal lenge (Campo et al., 
1993) and therefore E7-specific T cells were detected 
before and during the period of regression. There were 
few animals whose T cells gave stimulation indices 
above 2 at 21 and 25 weeks after challenge. At 29 weeks 
E7-specific T cells could be detected in 9 animals but 
only in 3 animals by 33 weeks. There appeared to be a 
biphasic response in most vaccinated an imals  over the 
course of the infection peaking between 7 and 17 weeks 
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FIG. 2--Continued 
29 33 
and 29 and 33 weeks. Individual animals varied in the 
timing and magnitude of their response to E7. PBM from 
animals in the control group showed little response to 
E7 at all time points (Fig. 2D). E7-specific T cells could 
be detected in animal 13 at 17 and 25 weeks postchal- 
tenge and a further 2 animals, 14 and 18, responded at 
25 and 29 weeks (Fig. 2D). The poor response to E7 in 
the control group at all the time points indicates that viral 
E7 is poorly presented to T cells in vivo, at least until the 
later stages of papilloma development. These results are 
Helper T cells recognise short linear peptides, approxi- 
mately 8-10 amino acids in length, presented on the 
surface of antigen-presenting cells in the groove of MHC 
class II molecules. To identify the immunodominant T 
T cell epitopes 
consistent with the low levels of F_7-specific antibodies 
in control animals and high levels in vaccinated animals 
(Chandrachud et al., 1994). 
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TABLE 1 
T CELL EPITOPES IN BPV-4 E7 
Experimental Weeks 
animal postchallenge T l (aa  31 59) T2(aa 70-88)  T3(aa 21 40) 
Vaccinated 
2 10,17 + 
3 17 + + 
5 17 + + 
6 7, 25, 29 - - 
7 10,13 - 
8 29 + - 
9 29, 33 - 
Total 4/7 2/7 
Controls 
13 17, 25 - - 
14 25, 29 - -- 
Total 0/2 0/2 
m 
+ 
1/7 
m 
0/2 
cell epitopes in E7, peptides were synthesised that cov- 
ered the entire E70RF (Fig. 1). Peptides were 19 or 20 
amino acids in length overlapping by 10 amino acids. 
PBM from frozen stocks of 7 vaccinated animals at the 
peak of their response to E7 in proliferation assays (Table 
1) were stimulated in vitro with E7 for 7 days and then a 
further 7 days with IL-2 to increase the population of E7- 
specific cells. The response to each of the peptides was 
then measured. While the response of individual animals 
was reproducible (Fig. 3) it varied between animals and 
was generally low, seldom achieving twice the control 
value even when the stimulation by E7 protein was high. 
PBM from 4 animals were positive to peptides covering 
the region aa 31-59. PBM from animals 2 and 8 were 
positive to peptide 167 (aa 37-55); PBM from animals 3 
and 5 were positive to peptide 161 (aa 31-49) and from 
animal 5 to peptide 162 (aa 41-59). The region aa 31-  
59 recognised by the majority of animals was defined 
as T1. Two animals were positive to other peptides but 
these were not dominant to the group and contain there- 
fore minor epitopes. PBM from animal 5 responded 
strongly to peptide 160 (aa 21-40), which has a 10- 
amino-acid overlap with peptide 161 (aa 31-49), and 2 
animals, 3 and 5, responded to peptide 165 (aa 70-88). 
The two minor epitopes, amino acids 70-88 and 21-40, 
have been defined as T2 and T3, respectively. Two con- 
tro] (nonvaccinated) animals, 13 and 14, that had a SI > 
2 to E7, were analysed for their response to the peptides 
at Weeks 17 and 25 for animal 13 and Weeks 25 and 29 
for animal 14. Individual peptides did not stimulate PBM 
from either animal above twice the control. The response 
of individual animals to the three epitopes is summarised 
in Table 1 and the epitopes are highlighted in Fig. 4. 
DISCUSSION 
We have previously shown that vaccination of cattle 
with BPV-4 E7 before challenge with BPV-4 has a thera- 
peutic effect, promoting early regression of papillomas 
(Campo etaL, 1993). It has been well documented that a 
vaccine should elicit both a humoral and a cell-mediated 
immune response (Tindie eta/., 1991). BPV-4 E7 appears 
to fulfill these requirements; high levels of E7-specific 
antibodies have been detected in the sera of cattle after 
vaccinatiOn (Chandrachud et al., 1994) and this paper 
shows that E7-specific T cells can be detected in the 
peripheral blood of cattle after vaccination at significantly 
higher levels than in nonvaccinated animals. Both the T 
cell and antibody responses to E7 are statistically differ- 
ent between the vaccinated and nonvaccinated groups 
(P-value < 0.001), confirming that vaccination with E7 
significantly enhances both the cell-mediated and hu- 
moral response to viral E7. The nature of the T cell re- 
sponse to E7 over time is difficult to assess due to the 
differences in timing and magnitude of the response in 
individual animals but this variability would be expected 
in an outbred population. The peak in T cell activity be- 
tween 7 and 17 weeks corresponds to the time of regres- 
sion of stage 2 papillomas in vaccinated animals. This 
suggests that E7-specific T cells may play a role in vac- 
cine induced early regression of papillomas but the 
mechanism of regression remains for the moment un- 
known. There was no unequivocal correlation between 
strength and timing of a proliferative response and the 
time of regression in individual animals. As the vaccine 
was administered as exogenous protein, it is likely that 
the activated T cells detected in the proliferation assay 
are helperT cells stimulated in an MHC class II restricted 
manner, although other cell types cannot be ruled out. 
Cattle have a high level of CD2- CD4- CD8 T cells 
with ~,~ T cell receptors, associated with protection of 
epithelial surfaces (Hein and Mackay, 1991); these cells 
could contribute to the response to E7 and papilloma 
regression. 
In nonvaccinated cattle there is a weak T cell response 
to E7, which is consistent with the low levels of E7- 
specific antibodies detected in the animals (Chandra- 
chud et al., 1994). These observations show that viral E7 
is poorly presented to the immune system, at least until 
the later stages of papilloma development. BPV-4 infects 
keratinocytes which do not possess MHC class II and, 
as infection does not kill the cell, presentation to T helper 
cells may be limited. 
The bovine model demonstrates that vaccination with 
BPW4 E7 induces regression of BPV-4 papillomas and 
this is accompanied by a significant humeral and cell- 
mediated response to E7. Studies with HPV-16 E7 in 
rodent models have shown that E7 acts as a tumour 
rejection antigen (Meneguzzi et al., 1991; Chen et aL, 
1991) and induces a delayed-type hypersensitivity re- 
sponse (McLean eta/., 1993). Both antibodies and T cells 
specific for HPV-16 E7 have been detected in mice (Com- 
merford eta/., 1991; Shepherd eta/., 1992; Tindle etaL, 
1991) and HPV-16 E7-specific T cells have been reported 
in seropositive patients (Altmann et a/., 1992). Taken to- 
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in vitro with E7 and then used in proliferation assays with peptides (158-167) as antigen at 4 fig~well in the presence of autologous irradiated 
PBM as antigen-presenting cells. Assays were in triplicate and [3H]thymidine incorporation was measured and presented as stimulation indices. 
The experimental number of each animal is next to the symbol box. The response of PBM to E7 is represented on the graph and SI are written 
above each bar. SI = cpm peptides/cpm (no antigen). 
gether, our results and those from other laboratories 
strongly suggest that E7 is a potential candidate for ther- 
apeutic vaccination against papi l lomavirus infection in 
humans. 
From peptide mapping studies BPV-4 E7 appears to 
contain at least one immunodominant T cell epitope (T1) 
recognised by the majority of animals and two minor 
epitopes (T2 and T3) recognised by only one or two ani- 
mals. T1, because of its length, 29 amino acids, may 
contain more than one epitope. No single peptide was 
recognised by all the animals; however, variabil ity in re- 
sponse to the peptides is net surprising in an outbred 
population where there are differing MHC alleles. T cell 
epitopes have been mapped on HPV-16 E7 along 75% 
of the protein length (Commerford eta/., 1991; Shepherd 
et al., 1992; Tindle et aL, 1991; Altmann et al., 1992) 
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Rb Zn 
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FIG. 4. Amino acid sequence of BPV-4 E7 with the T cell epitopes 
and functional domains highlighted. Solid lines above the sequence 
represent functional domains and below the sequence major T cell 
epitopes; dashed lines below the sequence represent minor T cell 
epitopes. 
and differences in response to E7 peptides have been 
reported in different strains of mice (Shepherd et al., 
1992). The T cell epitope defined in BPV-4 E7 as being 
immunodominant covers part of the putative pl05Rb 
binding domain and the putative Zn 2+ binding domain 
(Fig. 4), areas which have high amino acid homology with 
HPV-16 E7 (Jaggar et al., 1990; Jackson et al., 1991). 
Whether BPV-4 E7 and HPV-16 E7 have similar immuno- 
logical characteristics remains to be determined, but the 
results with BPV-4 E7 give hope that HPV-16 E7 may 
have a similar effect in inducing papilloma regression in 
humans. 
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